Gene therapies are truly game-changing treatments, often creating an opportunity for a healthy, normal life for people who previously had no options. But there are many challenges when it comes to administering them at scale.
Perhaps no example highlights both those realities as well as Sumitomo’s gene therapy RETHYMIC for children with congenital athymia.
At Reuters Pharma USA last week in Philadelphia, Blair McNeill, SVP and head of cell therapy for Sumitomo Pharma America spoke with pharmaphorum editor-in-chief Jonah Comstock about the difficulties of collecting donations and administering an allogeneic gene therapy like RETHYMIC.
They talk about why Sumitomo decided it needed to create its own manufacturing operation, rather than working with a partner, and discuss how this particular case can inform larger trends and lingering questions about gene therapy.
View the full conversation, and stay tuned for more video interviews from the show.
Subscribe to the pharmaphorum KZread channel for in-depth conversations with innovators across healthcare: / @pharmaphorum
Join us on Twitter for the latest news, features, event coverage, and discussions: / pharmaphorum
And for everything, everywhere, all at once, visit our official site: pharmaphorum.com/